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Malaria is one of the world’s deadliest diseases
and one of the world’s leading causes of sickness
and death. The disease causes more morbidity than
mortality in adults and has a propensity for clinical
relapse and recurrence. According to the World
Health Organization, the estimated annual global in-
cidence of malaria is 300 to 500 million cases of
malaria with ca. 1.5 to 2.7 million deaths, mostly in
infants, children, and pregnant women. Although
typically an illness of tropical regions of the world,
more cases (nearly all foreign-originating) are diag-
nosed in temperate countries each year. With its glo-
bal grip and the concomitant increase in travellers,
trade, and business, malaria has also now become
a global occupational disease, especially in seafarers.
By the nature of their job they cannot avoid malarial
regions and generally suffer from a lack of medical
help aboard, insufficient knowledge of preventive
measures, and lack of up-to-date information about
chloroquine-resistant areas. Malaria is listed as one
of the leading causes of fever resulting from travel to
tropical or subtropical countries. This article outlines
a strategy to assist in formulating a protocol for pro-
phylaxis aimed at prevention and immediate treat-
ment in seafarers.
Sub-Saharan Africa is the region with the highest
malaria infection rate. Here alone, the disease kills
at least one million people each year. According to
some estimates, 275 million out of a total of 530 mil-
lion people have malaria parasites in their blood, al-
though they may not develop symptoms [5, 6]. In the
early 1960s, only 10% the world’s population was at
risk of contracting malaria. This rose to 40% as mos-
quitoes developed resistance to pesticides and ma-
laria parasites developed resistance to treatment
drugs [5]. According to material from Third World
Network Features, in Africa alone, direct and indi-
rect costs of malaria amounted to US $800 million in
1987 and are expected to reach US $1.8 billion an-
nually by 1995 [4, 2]. The economic and human
costs Involved in dealing with an outbreak of mala-
ria on a ship that has just left the West African Coast
[1] (Figure 1), are huge as the disease can cause
loss of life and severe incapacitation as well as loss
of crew members both from incapacity and from the
care needs of those who are unwell. Diversion to
obtain medical care or evacuation of ill crew mem-
bers may also be needed. Malaria is now spreading
to areas previously free of the disease. Actually, ma-
laria transmission occurs in more than 100 coun-
tries throughout Africa, Asia, Latin America, and on
certain Caribbean and Pacific islands. Malaria is pre-
sently endemic in most countries around the equa-
tor, in areas of Central and South America, many
parts of Asia, especially in South East Asia, and most
areas of sub-Saharan Africa, where up to 90% of all
malaria fatalities occur. The geographic distribution
of malaria is complex, and malaria-free or malaria-
-afflicted zones are very close to each other. Malaria
is much more common in rural areas than in cities
in most malaria zones, but, for instance, in Africa the
high risk exists in cities too. If the prevalence of ma-
laria stays on its present level, the estimated death
rate could even double in the next 20 years.
Malaria is an acute or chronic disease- prevent-
able, life-threatening disease transmitted by the bite
of the female Anopheles mosquito. Among more than
100 species of plasmodia there are five types of ma-
laria that affect humans: Plasmodium falciparum
(which is responsible for the vast majority of malaria
deaths), Plasmodium vivax, Plasmodium ovale, Plas-
modium malariae, and Plasmodium knowlesi.
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MALARIA ENDEMICITY
Holoendemic malaria occurs when transmission
is all year long: hyperendemic — transmission intense,
but with periods of no transmission during the dry
season; mesoendemic — regular seasonal transmis-
sion (unstable malaria); and hypoendemic — when
very intermitted transmission occurs. Stable P. fal-
ciparum malaria occurs in holoendemic and hy-
perendemic areas; anaemia and high childhood mor-
tality is seen. Adults living in these areas show some
resistance, and many of them are asymptomatic. For
unstable malaria many adult symptomatic cases are
typical and high risk of fatalities occurs. In these ar-
eas there are seasonal and periodic epidemics. In
most of sub-Saharan African countries there is mainly
holo- and mesoendemic malaria [4, 9].
Malaria infection is not a risk at sea or on off-
shore oil terminus facilities that are distant from shore,
provided that no female Anopheles mosquitoes have
boarded the vessel or laid their eggs there. However,
docking in many ports may place crew members at
risk, whatever their background or previous expo-
sure, particularly if they go ashore [3, 10, 12, 13].
Similarly, transits through infected areas when joi-
ning ships or whilst on leave may give rise to cases
onboard. Immunity to malaria is not lifelong and so
even those who had immunity from past exposure
will very likely lose it and become vulnerable to re-
infection with severe consequences after a period at
sea or in non-malarial areas. There are several diffe-
rent strains of malaria, and exposure to one does
not protect against the others. Falciparum malaria
can be rapidly life threatening. It is common in many
areas of the tropics, and an especially high level of
precaution is needed to prevent exposure in loca-
tions where it is present. The clinical picture of the
disease is highly variable but is generally character-
ized by periodic paroxysms of fever and chills,
anaemia, and splenomegaly. Any fever must be ob-
served with suspicion and the test, if a kit is available
on board, must be carried out immediately. Rapid
diagnosis is made by immunochromatographic test
that detects malaria antigens (sensitivity 90–95%,
specificity 72–92%). In case the kit is unavailable,
treatment on suspicion is justifiable. Nevertheless,
final microscopic diagnosis is necessary in a profes-
sional lab.
Symptoms appear seven days or more (usually
10–15 days) after the infective mosquito bite. The
first symptoms — fever, headache, chills, and vomit-
ing — may be mild and difficult to recognize as ma-
laria. If not treated within 24 hours, P. falciparum
malaria can progress to severe illness often leading
to death. Children in endemic areas with severe dis-
ease frequently develop one or more of the following
syndromic presentations: severe anaemia, respirato-
Figure 1. Malaria’s global grip. Between 300 million and 500 million acute cases of malaria are reported each year — 9 out of 10
of them occur in sub-Saharan Africa. Dark: current malaria transmission. Grey: malaria largely eliminated. White: malaria not
present
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ry distress in relation to metabolic acidosis, or cere-
bral malaria. In adults, including seafarers, multi-or-
gan involvement is also frequent.
VACCINES
The French scientist Laveran may have discovered
the malarial parasite plasmodium way back in 1880;
however, a vaccine against malaria is still far off. There
is a global need for this vaccine and intense research
is in progress to make the same available. There are
several vaccine development projects in progress
worldwide [2] and it may well be another 5 to 7 years
before the vaccine will reach markets. Infants and
children living in malaria endemic areas will be the
first target group for the vaccine. Seafarers, travel-
lers, and those living in malaria endemic areas will
be the next target group to whom the vaccine will be
made available. However, it has to be understood
that the vaccine, when available, will only form part
of a malaria preventive strategy.
In India, scientists like Chetan Chitnis from the
International Centre for Genetic Engineering and
Biotechnology (ICGEB) [7] at New Delhi, along with
his team, are trying hard to make the vaccine reach
the phase I trial as soon as possible. Working with
Plasmodium, the malarial parasite, is difficult as the
organism undergoes fast mutations and the vaccine
has to cover several species of the parasite. The de-
velopment of resistance is one more hurdle to cross.
Despite this, scientists have picked up the gene se-
quence which does not change with mutation and
have made the vaccine work at the laboratory level
for both plasmodium vivax and falciparum. Scientists
of the US Naval Medical Research Team in Djakarta
[11] have independently established the development
of antibodies to the circumsporozoite protein, which
are important in reducing the prevalence of malaria
with increasing age among persons in areas in which
malaria is endemic, and have shown that the vac-
cine-elicited antibody to the circumsporozoite repeat
region does indeed protect against infection with
P. falciparum sporozoites.
The most advanced vaccine candidate to date is
the RTS,S, which has shown a promising safety and
tolerability profile in infants and is the first „proof of
concept” of a malaria vaccine. In African infants the
vaccine shows protection against malaria. The vac-
cine has gone through the Phase I and Phase II trials,
and the Pivotal Phase III evaluation was started in
May 2009. The most recent results were published in
the New England journal of Medicine on 11 October
2011 [14]. The largest study yet of its effectiveness
found it cut cases of malaria by half in children aged
between five months and 17 months. Interim results
from the study — which is still under way and involves
more than 15,000 babies and children in seven Afri-
can nations — found the vaccine cut all episodes of
malaria by 55%, and cases of severe malaria by 35%.
According to Jo Cohen (co-inventor of RTS,S from Gla-
xoSmithKline), the first broad implementation of vac-
cine might be possible in 2015–2016 [15].
SEAFARERS AND SEAFARING
Cases of imported malaria acquired by interna-
tional travel and trade are increasingly reported. The
mean annual incidence of imported malaria in Eu-
rope only reaches a level of ca. 12,000 cases. Travel
has contributed to the global spread of malaria
throughout the history of humankind. Travellers, and
notably seafarers, visiting malaria risk areas should
be properly advised on personal protective measures
and chemoprophylaxis. It is probably not practical or
appropriate for crew members in tropical regions to
remain on malaria prophylaxis continuously, but ju-
dicious use of prophylaxis when the risk is greatest
is probably the most effective way of minimizing the
chances of acquiring malaria for merchant seamen.
This is the thinking behind this strategy, to provide
a policy in the form of guidance for intermittent pro-
phylaxis when there is sufficient risk of malaria. It
recommends a limited number of prophylactic drugs
for simplicity and greatest efficacy. Both Malarone
and doxycycline are well tolerated and generally safe.
Use Malarone first. Doxycycline may be used as an
alternative if intolerant to Malarone. The guidelines
below are adapted from the existing [5] recommen-
dations developed for seafarers by a UK based com-
pany. Ours below are divided into three sections:
Section 1 deals with the prevention and treatment
principles, Section 2 categorizes the risk, and Sec-
tion 3 outlines the prophylactic and treatment mea-
sures, depending on geographical areas of travel.
Those most likely to benefit from this strategy are
the seafarers themselves, maritime doctors, ship op-
erators, and port agents. Responsibility for knowledge
and adherence to current preventative and treatment
options lies with the latter two and to a lesser degree
with the seafarer. The ship must be compliant with
the relevant ILO/IMO and port safety codes. The
Master of the ship is responsible for drawing up
a recommendation for shore visits, the wearing of
protective clothing, use of mosquito repellents, closing
of doors and windows pre dusk, reporting of fever,
lethargy, etc., and location on vessel in evenings when
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in port. In addition, the Master of the vessel must
also issue other deterrents for non-compliance.
PROTOCOL FOR THE AVOIDANCE,
PROPHYLAXIS, AND TREATMENT
OF MALARIA ON BOARD SHIP
How to use this recommendatory manual:
1. Ensure that those working in malarial areas and
those responsible for their care are aware of the
steps that need to be taken to prevent and treat
malaria (Section 1).
2. Look up [port] on the list which is region-wise and
check the risk of malaria — Category 0, 1, 2, 3
(Section 2).
3. Follow instructions on prophylaxis and treatment
(Section 3).
SECTION 1: PREVENTION
AND TREATMENT PRINCIPLES
The key to malaria control in crew members is:
1. Avoidance of mosquito bites
2. Appropriate prophylaxis
3. Diagnose early in unwell crew
4. Treat
1 . Avoidance of malaria: Requires A, B, C, and D
• Awareness of risk
• Bite avoidance
• Chemoprophylaxis (taking preventive medicines
if you are travelling to or living in a malaria re-
gion)
• Diagnosis made promptly with early treatment of
an infected case
An E can be considered for seafarers in medium-
and low-risk areas and those on remote adventure trips.
The E stands for “Emergency treatment with safe drugs”,
such as Artemesin combined with Lumefantrine [8].
Living and working accommodation onboard
which is sealed and air-conditioned will be safe from
malaria if mosquitoes are kept out. Consider spray-
ing rooms and cabins with pyrethroid insecticides if
doors and windows have been left open for signifi-
cant periods particularly at dusk when in ports where
there is a high risk of malaria (West and East Africa,
parts of SE Asia).
Working on deck or being on shore will increase
the risk of acquiring malaria. Long-sleeved clothing,
long trousers, and socks should be worn out of doors
after sunset. Light colours are less attractive to mos-
quitoes. Insect repellents containing over 30% DEET
will repel mosquitoes effectively and should be ap-
plied to exposed skin. Impregnating cotton garments
with 30 ml of DEET in 250 ml of water makes them
repellent. Refined lemon eucalyptus oil on skin also
repels mosquitoes [15, 16].
When ashore sleep in rooms that are properly
screened, with close fitting gauze over windows and
doors, no holes in the gauze, and no unscreened
entry points. Spray the room with a knockdown in-
secticide ca. one hour before evening to kill any
mosquitoes that may have entered the room during
the day. When sleeping outdoors or in an unscreened
room, use mosquito nets around the bed at night,
checking that there are no holes in the net. The net
should be impregnated with pyrethroids, such as
permethrin 0.2 g/m2 of material every six months,
and the net should be long enough to fall to the
floor all round the bed or be tucked under the mat-
tress. Synthetic pyrethroids should be vaporised over-
night, using an electrically heated mat. Alternatively,
mosquito coils (slow burning mixture of repellent and
insecticide) may be burned. Electronic buzzers are
sometimes marketed as repellents, but they are not
effective [16].
SECTION 2: [PORTS] AND THEIR RISKS
[Ports] and specific recommendations
Check risk category level (0, 1, 2, or 3) on port list
and follow the specific recommendations below.
Category 3: High-risk areas — substantial risk of acquiring malaria
Areas East Africa south to Mozambique, West Africa south to Namibia, Oceania (PNG), NE South America,
SE Asia
Avoidance Follow policy above
Prophylaxis for All crew members to take Malarone for one day before arrival in port, for the duration of docking, and for
crew on board 7 days after leaving port
Prophylaxis for All shore-based crew to take Malarone for one day before arrival on shore, for the duration of shore visit,
crew on shore and 7 days after leaving port. An alternative is doxycycline for 2 days before shore visit, the duration of
visit, and 4 weeks after leaving
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SECTION 3: MEDICATION
FOR PROPHYLAXIS AND TREATMENT
Prophylaxis
It is probably not practical or appropriate for crew
members in tropical regions to remain on malaria
prophylaxis continuously, but use of appropriate pro-
phylaxis when the risk is greatest is probably the most
effective way of minimizing the chances of acquiring
malaria for merchant seamen. The purpose of this
policy is to provide guidance for intermittent prophy-
laxis when there is sufficient risk of malaria. It rec-
ommends a limited number of prophylactic drugs
for simplicity and greatest efficacy. Both Malarone
and doxycycline are well tolerated and generally safe.
Use Malarone first. Doxycycline may be used as an
alternative if a person is intolerant to Malarone [8].
Other agents which can be used are described
in the text below [15] and include:
• Proguanil plus chloroquine
• Mefloquine (Lariam)
• Dapsone/Pyrimethamine (Maloprim)
Atovaquone/proguanil (Malarone)
Dose: One tablet daily — start day before en-
tering malarious area and continue for one week
after leaving.
This fixed combination of atovaquone 250 mg with
proguanil 100 mg has been an effective treatment for
highly chloroquine-resistant falciparum malaria for some
years. Some apparent failures of prophylaxis have been
recorded, but it is unclear whether they involve actual
resistance to atovaquone/proguanil. One tablet daily is
taken for prophylaxis. The side-effect profile appears
comparable with that of the other antimalarials, as lis-
ted above, but serious adverse effects appear rare. The
drug is expensive, but the reduced period of prophy-
laxis (one week post exposure) means that the overall
cost is similar to that of mefloquine for short visits to
malarious areas, as would be seen with seafarers.
Doxycycline
Dose: One tablet (100 mg) starting one week
before entering malarious area and continuing
for 4 weeks after leaving.
An antibiotic of the tetracycline group is active
against falciparum malaria but offers limited pro-
Category 2: Moderate-risk areas
Areas India, Horn of Africa, Tropical South America, Central America, Indian Ocean Islands, Remote parts
of Oman (Muscat itself is malaria-free), parts of Saudi Arabia, Yemen, Iran, and Afghanistan
Avoidance Follow policy above
Prophylaxis for No specific prophylaxis required. Avoid mosquito bites
crew on board
Prophylaxis for All shore-based crew to take Malarone for one day before arrival on shore, for the duration of shore visit,
crew on shore and 7 days after leaving port. An alternative is doxycycline for 2 days before shore visit, the duration
of visit, and 4 weeks after leaving
Category 1: Low-risk areas
Areas North Africa, Arabia, Eastwards along the coast from Antalya to the Syrian border and inland in southeast
Turkey, and in parts of Syria and Iraq. South Africa (ports are safe)
Avoidance Follow policy above
Prophylaxis for No specific prophylaxis required. Avoid mosquito bites
crew on board
Prophylaxis for No specific prophylaxis required. Avoid mosquito bites. If travelling for prolonged periods inland, further
crew on shore advice may need to be taken from a travel health expert. If in doubt, take malaria prophylaxis — Malarone
or doxycycline for duration of visit as above
Category 0: Malaria NOT a risk
Areas Europe, North America, Australia,
New Zealand, southern S. America
Avoidance Not necessary
Prophylaxis for No prophylaxis required
crew on board
Prophylaxis for No prophylaxis required
crew on shore
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tection against P. vivax. It, or atovaquone/progua-
nil, are the drugs of first choice for prophylaxis in
areas of mefloquine-resistant malaria in Southeast
Asia, and are alternative drugs to mefloquine for
people visiting highly chloroquine-resistant areas,
which are along the coasts of Africa, South Ameri-
ca, India, and some parts of South East Asia. Photo-
sensitivity may be a problem in some people. Exfoli-
ative dermatitis has been reported but is rare. Ex-
cessive exposure to sun should be avoided by people
on tropical seaside holidays, but effective sun-
screens are now widely available. Doxycycline may
cause diarrhoea but also may protect against some
bacterial causes of travellers’ diarrhoea. People
using doxycycline should be warned against expo-
sure to too much sunlight. Doxycycline should not
be given to anyone with a history of allergy to tetra-
cycline. Oesophagitis (heartburn) may result from
taking the capsule on an empty stomach and/or
lying down too soon after taking it. Compliance with
the daily dose regimen appears to be particularly
important with doxycycline.
Standby treatment
1. If malaria is expected based on:
a. Exposure to malaria having been in a malar-
ious area;
b. Fever > 38oC, in paroxysms, often with flu-like
symptoms of muscle aches, headaches.
2. Check diagnosis by doing finger prick blood test
using the malaria test kit, following the product
instructions carefully. If no kit is available on board,
then treat empirically for malaria, if the above
symptoms and relevant geographical history are
present. It is advisable to make blood slides (thick
and thin blood slides to be examined in the near-
est qualified lab).
3. Seek Radio Medical Advice if available.
4. If positive result, start anti-malarial treatment im-
mediately with: quinine 2 tablets 3 times a day
for 3 days, plus one tablet of doxycycline twice
daily for 7 days.
Other standby treatments are available.
Standby treatment table 1 from [15]
CONCLUSIONS
Human infection with Plasmodium species leading
to clinical episodes of malaria probably began very
early in the history of humankind and has persis-
tently inflicted disease among human populations.
Malaria is currently considered the world’s most im-
portant parasitic infection. The global impact of ma-
laria is incalculable and appears to have increased
over the past few decades. Most of this burden of
disease is carried by developing tropical countries.
These numbers are growing because of increased
travel to malaria-endemic areas and also due to in-
creased risk of transmission in these areas. Non-ad-
herence to chemoprophylactic regimens is frequently
secondary to drug side effects. Therefore, a careful
risk-benefit analysis on the use of anti-malarial pro-
phylaxis should be carried out in every individual
travelling to malaria risk areas. Standby malaria self-
-treatment is not an alternative in seafarers travel-
ling to relatively low-risk areas. The goal of the above
recommendation is to be simple yet practical and to
provide a resource for the seafaring community, es-
pecially medical physicians seeking Malaria informa-
tion. It thereby strives to address the main issues of
Table 1. Standby treatment table from reference [9]
Situation for use Standby treatment regimen Usual amount per tablet Adult dose
Multidrug-resistant Atovaquone-proguanil 250 mg plus 100 mg 4 tablets as a single dose on
falciparum malaria (Malarone) each of three consecutive days
Multidrug-resistant Co-artemether (Riamet) 20 mg artemether plus 6 doses of 4 tablets over
falciparum malaria 120 mg lumefantrine a period of 60 hours
Multidrug-resistant Quinine plus doxycycline 200 mg quinine and Quinine 2 tablets 3 times a day
falciparum malaria 100 mg doxycycline for 3 days, accompanied by
1 tablet of doxycycline twice
daily for 7 days
Recommended Chloroqiune 150 mg chloroquine base 4 tablets on days 1 and 2,
where no chloroquine (Nivaquine/Avloclor) (Nivaquine) or 155 mg 2 tablets on day 3
resistance present chloroquine base (Avloclor)
Pregnancy Quinine 300 mg quinine Quinine 2 tablets 3 times
a day for 5–7 days
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malaria and reduce the morbidity and to a lesser
extent the mortality, in seafarers. The IMHA as an
International Maritime Health Advisory Body can as-
sist the stakeholders upon requests or advice for de-
veloping specific Malaria Protocols.
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